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  The 23 open reading frame (ORF) 5 sequences of Korean 
type  II  porcine  reproductive  and  respiratory  syndrome 
virus (PRRSV) were collected from viremic sera  from the 
(modified live vaccine) MLV-vaccinating and non-vaccinating 
farms from 2007 to 2008.  The samples were phylogenetically 
analyzed with previous ORF5 sequences, including type I 
Korean  PRRSV,  and  previously  reported  or  collected 
sequences from 1997 to 2008.  A MN184-like subgroup of 
type II Korean PRRSV was newly identified in the viremic 
sera  collected  from  2007  to  2008.  And  of  the  type  I 
PRRSVs, one subgroup had 87.2∼88.9% similarity with 
the Lelystad virus, showing a close relationship with the 
27∼2003 strain of Spain. The maximum parsimony tree of 
type II PRRSV from 1997 to 2008 showed that they had 
evolved to four lineages, subgroups 1, 2, 3 and 4. Most of 
the  recently  collected  type  II  PRRSVs  belonged  to 
subgroup 4 (48%). The region of three B-cell epitopes and 
two T-cell epitopes of ORF5 amino acids sequences was 
considerably different from the MLV in subgroups 3 and 
4. In conclusion, the existence of type I PRRSV, which was 
genetically  different  from  Lelystad  virus  (Prototype  of 
type  I  PRRSV),  and  heterologous  type  II  PRRSVs  of 
viremic pigs detected even in the MLV-vaccinating farms 
indicated  the  need  for  new  vaccine  approaches  for  the 
control of PRRSV in Korea.
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Introduction
Porcine reproductive and respiratory syndrome virus 
(PRRSV) is a small, enveloped RNA virus [4,39] that is 
classified as a member of the genus Arterivirus of family 
Arteriviridae in the order Nidovirales [6]. PRRSV was first 
isolated almost simultaneously in Europe [40] and the 
USA [9].
  The PRRSV genome is a polyadenylated, single-stranded, 
non-segmented, positive-sense RNA approximately 15 kb 
in size and consisting of at least 9 open reading frames 
(ORFs) [10,27,30,35,41]. ORF1a and 1b are located 
immediately downstream of the 5’ untranslated region 
(UTR) and involved in virus transcription and replication. 
ORFs 2 to 7 are located at the 3’ end of the genome and are 
thought to encode for the PRRSV structural protein. 
Among them, ORF5 encodes an unglycosylated membrane 
of 17 kD or a glycosylated protein of 25 kD [22,26]. 
Furthermore, the ORF5 of PRRSV is in an immunologically 
crucial region which is mainly related with neutralizing 
antibody formation.  In the case of type II PRRSV, ORF5 
has been known to contain three B-cell epitopes and two 
T-cell epitopes [11,31,32,38].  
    Remarkable genetic differences have been reported 
among PRRSV. The major two genotypes are European 
(Type I, Lelystad as prototype) and North American (Type 
II, VR-2332 as prototype). The similarity between these 
two genotypes among the ORFs were shown to be 57∼
59% (ORF7), 70∼81% (ORF6), 51∼59% (ORF5), 68% 
(ORF4), 58% (ORF3) and 63% (ORF2) [3,14,23,24,25,28]. 
Even within the same genotype, high genetic variation 
among field viruses has been reported all over the world.  
Type II PRRSV was first isolated in Korea in 1994 [21], 
with the molecular characterization of Korean PRRSV 
from 1996 to 2006 based on ORF5 and ORF7 [7,8,43]. 122    Hye Kwon Kim et al.
Table 1. The information of type II porcine reproductive and respiratory syndrome virus (PRRSV) open reading frame (ORF) 5 
sequences in the sera of viremic pigs from 2007 to 2008
MLV vaccination Vaccine scheme* Farm-I.D
† Stage of pigs Disease info.
∥ Year
MLV vaccinating Sow    3913-6 5
‡ PCV2
†¶ 2008
   3922-5 9 Respiratory sign at 14 weeks of age 2008
   3931-1 3 N.D** 2008
   3958-4 6 PCV2 + Severe wasting after nursery 2008
   4015-5 9 PCV2 +, 30% mortality in nursery period 2008
   4051-3 6 Anorexia of sows and wasting and  2008
  diarrhea in nursery period
   4033-12 3 N.D 2008
   MG-1 N.D N.D 2007
   PS4-15 6 5% mortality in pigs 2007
   PS6-11 12 17% mortality in nursery period 2007
   PS7-8 6 5% mortality in pigs 2007
Sow/piglet    3983-3 8 N.D 2008
   PS9-9 9 High mortality at 10∼12 weeks of age 2007
Gilt    4034-2 6 Diarrhea at 5∼7 weeks of age 2008
   4048-9 8 Diarrhea in suckling piglets 2008
Non-vaccinating 򰠏    3903-3 8 Wasting at 4∼8 weeks of age 2008
   3755 6 Wasting and diarrhea 3∼4 weeks after nursery 2008
   4013-1 Sow N.D 2008
   4010-5 7 Wasting at 6∼9 week of age 2008
   4011-3 6 N.D 2008
   4036-1 7 PCV2 +PMWS at 4∼10 weeks of age 2008
   PS1-9 9 18% mortality in nursery period 2007
   PS5-7 Nursery
§ N.D 2007
*Modified live vaccine (MLV) vaccinating scheme : Sow (MLV vaccination on the sow group only, usually at nursery or mass vaccination with
3 months of interval), Sow/Piglet (MLV vaccination on sows and piglets at 2∼4 weeks of age), Gilt (MLV vaccination on the gilts in the 
acclimatization). 
†I.D of farms - I.D of pooled sera which were pooled with 2 or 3 individual sera in the same age. 
‡Weeks of age. 
§Piglets 
around 3∼4 weeks of age. 
||The disease information of the farm at the time of blood sampling. 
¶PCV2-positive in the tissue sample with PCR
method at the time of blood sampling. **N.D: No data available.
These studies suggested that the Korean PRRSVs belonged 
to the Type II PRRSV and had geographically evolved with 
their own genetic clusters. However, one group also 
reported that type I PRRSV also existed in Korea [18]. 
    To control PRRSV, the modified “test and removal 
method” was successful in the seed stock breeding farm 
and a supplying boar studs in Korea [42]. Since this method 
is laborious and time-consuming, most swine farms with 
continuous flow systems have applied a modified live 
vaccine (MLV) .
  With the widespread use of MLV, the actual efficacy of 
the vaccine came into question as the sequence analysis 
based on the ORF5 sequences of Korean PRRSV showed 
that the genetic divergence was ranged from 1.3 to 12.9% 
compared to the MLV [7]. Although MLV had an effect to 
reduce clinical signs and enhance weight gain in the 
PRRSV-infected farms, the virus shedding of challenged 
heterologous viruses was not prevented [5]. 
  With these concerns, this study focused on analyzing the 
patterns of viremia detected post-vaccination, which could 
represent the active replication of PRRSV, in the either 
MLV vaccinated or non-vaccinated farms. Furthermore, 
the full ORF5 sequences acquired from viremic pigs were 
compared with the reported [7,21] or previously collected 
data in the laboratory including type I and II PRRSV from 
1997 to 2008. 
Materials and Methods
Study design
  Blood samples were collected from commercial swine 
farms with information about MLV vaccinating and 
disease status.  In the case of MLV vaccinating farms, 
blood samples were collected at least 6 months after the 
first vaccination. If the main clinical signs and PCV2- 
specific PCR results were available, they were also 
documented (Table 1).
  At first, pilot study was performed to preview the viremic Genetic analysis of ORF5 of recent Korean PRRSVs    123
Table 2. Information of laboratory data of Korean PRRSV ORF5 sequences from 1999 to 2008
I.D Source of sequences Year Type I.D Source of sequences Year Type
CP07-401-9 Isolated on MARC-145  2007 II IV1158 Lung 2003 II
CP07-626-2 Isolated on MARC-145  2007 II BI954 Lung 2003 II
MG-1 Tissue homogenate  2007 II BI955 Lung 2003 II
BI19 Lung  1999 II BI991 Lung 2003 II
BI378 Lung  1999 II BI1177 Lung 2003 II
E482 Lung  2000 II M1102 Lung 2003 II
BI560 Lung  2000 II BI885 Tissue homogenate 2002 II
BI563 Lung  2000 II BI827 Lung 2002 II
IV492 Lung  2000 II BI747 Lung 2002 II
BI596 Lung  2000 II E1173 Lung 2003 II
BI598 Lung  2000 II E1174 Lung 2003 II
BI548 Lung  2000 II E1175 Lung 2003 II
BI674 Tissue homogenate  2001 II A1887 Tissue homogenate 2008 I
BI904 Tissue homogenate  2002 II A1923 Tissue homogenate 2008 I
A1939 Tissue homogenate 2008 I
patterns in the MLV vaccinating and non-vaccinating 
farms. The vaccine schedules used in the MLV-vaccinating 
farms were one of the sow-only or sow/piglet vaccinations. 
Among 25 farms, the number of farms with viremic pigs at 
3, 6, 9 and 12 weeks of age, including sows, was investigated 
using a reverse transcriptase nested polymerase chain 
reaction (RT-nested PCR) method. Serum antibody titer 
was also evaluated with a commercial enzyme-linked 
immunosorbent assay (ELISA) kit (Herdchek 2XR, PRRS; 
IDEXX, USA).  The serum IgG titers were expressed as 
S/P ratio: (Sample O.D - Negative control O.D) / (Positive 
control O.D - Negative control O.D).
  After the pilot study, to know the genetic properties of 
PRRSV in the viremic sera between MLV-vaccinating or 
non-vaccinating farms, the viremic samples collected from 
2007 to 2008 were further sequenced based on ORF5. A 
total of 23 PRRSV ORF5 sequences in the viremic sera 
were obtained. The sequenced data was analyzed with 
reference and previous laboratory sequence data including 
type I and II PRRSV from 1997 to 2008, to observe the 
phylogenetic relationship. The detailed sequence information 
was presented in Tables 1 and 2.
  Except for previously-published reference sequences, the 
sequence data of type I PRRSV and the other type II 
PRRSV (not collected from viremic sera) used in this study 
were collected from 1999 to 2008 in the virus-infected 
tissues of commercial pigs in Korea. The ORF5 sequences 
used in this study are available in GenBank accession 
numbers, from FJ972714 to FJ972766.
Virus isolation
  Two Korean field isolates (CP07-401-9 and CP07-626-2, 
both in 2007) were adapted on MARC-145 cell which was 
known to be permissive to the PRRSV, especially type II 
PPRSV [15] and used for genetic analysis. Briefly, the 
tissue homogenates suspended 10% by volume in Dulbecco’s 
minimum essential medium (DMEM) and centrifuged. 
The supernatant was filtered with syringe filter (0.45 μm; 
ChmLab, Spain) and used to inoculate the MARC-145 
cells grown in DMEM containing penicillin (100 
units/ml), streptomycin (100 μg/ml) and amphotericin B 
(0.25 μg/ml) with 10% fetal bovine serum (FBS). After 2 h 
incubation at 37.5
oC and washing with phosphate  buffered 
saline (PBS, pH 7.4), maintenance medium (DMEM with 
5% FBS) was added. The suspicious virus candidates were 
in continuous passage with the same manner after 5∼7 
days of incubation until the cytopathic effect (CPE) was 
observed. When the CPE was observed, the PRRSV was 
identified by PRRSV-specific RT-nested PCR [20] and 
immunofluorescence assay (IFA). The IFA kit was kindly 
given from National Veterinary Research Quarantine 
Service (Korea).
RNA  extraction  from  the  PRRSV  isolates  and 
collected sera
  In this study, the all collected sera were made to a pooled 
sample with 2 or 3 individual sera in the same age group. 
The pooled samples of 250 μl and culture medium of 
isolated virus (passage 3, both CP07-401-9 and CP07- 
626-2) was mixed with 750 μl of Trizol LS (Invitrogen, 
USA). In the case of virus infected tissues, 20% tissue 
suspension with PBS was made, and 250 μl of suspension 
was reacted with Trizol (Invitrogen, USA).  After 15 min 
incubation, 200 μl of cold chloroform was added, followed 
by vortexing. The vortexed mixture was centrifuged at 
12,000 g, 4
oC for 15 min and 450 μl of the supernatant was 
mixed with same volume of cold isopropyl alcohol. After 
precipitating overnight at 򰠏20
oC, the solution was centrifuged 124    Hye Kwon Kim et al.
Table 3. The information of primers used in this study
Type of
Use    Name Sequences Target region Product size References
target
 PRRSV I, II N21 5’-GTA CAT TCT GGC CCC TGC CC-3’ ORF6 to 3’non- 668 bp
  Detection N26 5’-GCC CTA ATT GAA TAG GTG AC-3’   coding region
 II N22 5’-TCG TTC GGC GTC CCG GCT CC-3’ ORF6 to 7 349 bp [20]
N24 5’-TTG ACG ACA GAC ACA ATT GC-3’
  I N23 5’-CGC TGT GAG AAA GCC CGG AC-3’ 354 bp
N25 5’-TCG ATT GCA AGC AGA GGG AG-3’
 ORF5   II FR9 5’-GAC ACC TGA GAC CAT GAG-3’ ORF4 to 6 933 bp Designed 
Sequencing RR9 5’-TCT ATG GCT GAG TAC ACC-3’ for the study
RF5 5’-CCA TTC TGT TGG CAA TTT GA-3’ 716 bp [3]
RR5 5’-GGC ATA TAT CAT CAC TGG GA-3’
I ERT 5’-TAT GTI ATG C-3’( for cDNA synthesis) 719 bp [29]
EF5 5’-CAA TGA GGT GGG CIA CAA CC-3’
ER5 5’-TAT GTI ATG CTA AAG GCT AGC AC-3’
at 12,000 g, 4
oC for 10 min and the final RNA pellet was 
acquired by washing with 75% ethanol and centrifugation. 
The RNA pellet was dissolved with 30 μl of 0.1% diethyl 
pyrocarbonate-treated distilled water.
cDNA synthesis and RT-PCR
  The primers used in this study were presented in Table 3. 
The cDNA was synthesized with a commercial M-MLV 
reverse transcriptase kit (Invitrogen, USA) following the 
manufacturer’s instructions. The N26, RR9, ERT primers 
were used in the cDNA synthesis for virus detection and 
sequencing. To detect the viremic sera, a previously 
published RT-nested PCR method, which amplifies a part 
of ORF6 to ORF7 region, was used [20]. For the ORF5 
sequencing of type II PRRSV, a modified RT-nested PCR 
was used based on the published RT-PCR method [3]. 
Briefly, FR9 and RR9 primers were newly designed based 
on the ORF4 and ORF6 regions to generate a 933 bp 
fragment to include the complete ORF5 sequence. These 
PCR products were further amplified with two published 
primers, RF5 and RR5, as a nested PCR which produces 
716 bp fragment containing full ORF5 sequence.  
  The PCR reaction was performed with i-StarMaster mix 
PCR kit (iNtRON Biotechnology, Korea). The total mixture 
(20 μl) included 1 μl of each primer at a concentration of 10 
pmol/μl, 2 μl of cDNA and 16 μl of master mix containing 
250 mM dNTP, 2 mM Mg
2+, K
+ and NH
4+ were added as 
salts along with 10 mM Tris-HCl (pH 9.0) to the PCR tube, 
which was coated with 2.5 Unit of i-star Taq DNA 
polymerase. The first PCR was performed at 95
oC for 5 
min followed by 30 cycles of 95
oC 1 min, 55
oC 1 min, 72
oC 
1 min, with a final extension at 72
oC or 10 min, and then 
held at 4
oC.
  The nested PCR was performed using 2 μl of first PCR 
products as a template along with FR5 and RR5 primers. 
The protocol was as follows: 95
oC for 5 min followed by 30 
cycles of 95
oC 45 sec, 55
oC 45 sec, 72
oC 45 sec, with a final 
extension at 72
oC for 10 min, and then held at 4
oC. For the 
ORF5 sequencing of type I PRRSV from the infected 
tissues, RT-PCR was performed as described in a previous 
paper [29]. The PCR products were electrophoresed in a 
1% agarose gel containing ethidium bromide. The target 
bands were visualized using an ultraviolet lamp.
Sequencing and data analysis
    For sequencing ORF5, a 716 bp fragment of type II 
PRRSV and a 719 bp fragment of type I PRRSV were 
purified using the QIAquick Gel Extraction kit (Qiagen 
Korea, Korea). Both strands of purified products were 
sequenced by Genotech (Korea). The full ORF5 sequences 
were analyzed using CLUSTALX v1.83 program and 
MegAlign software (DNAStar, USA) to determine the 
phylogenetic relationships and nucleotide similarity. The 
Neighbor-joining tree and was drawn using Kimura-two 
parameter as a distance estimation and percent frequencies 
of the groupings were determined after 1,000 bootstrap 
evaluation. The Maximum parsimony tree was also drawn 
as a consensus tree after 1,000 bootstrap evaluations.
Results
Pilot  study  about  MLV  vaccination  and  viremic 
status in 2007
    The viremia of type II PRRSV was detected in both 
MLV-vaccinating and non-vaccinating farms (Table 4). In 
the non-vaccinating farms, most viremic pigs were found 
at 6 to 12 weeks of age. Even in the farms with MLV 
vaccination, PRRSV viremia was also detected regardless 
of vaccine schedule. The mean S/P ratio was relatively 
lower in the non-vaccinating farms than MLV-vaccinating Genetic analysis of ORF5 of recent Korean PRRSVs    125
Table 4. Pilot data about viremic patterns of type II porcine reproductive and respiratory syndrome virus (PRRSV) according to the 
MLV vaccinating schedule in Korea, 2007
Vaccine schedule* Estimating value
Stage of pigs
Sow 3 6 9 12
The vaccinated Sow No. of farms with viremic pigs 　0/8 　0/4
‡ 1/6 1/4 1/6
S/P ratio   1.37 ± 0.09
† 0.98 ± 0.20 0.62 ± 0.13 1.15 ± 0.24 1.52 ± 0.26
No. of tested pigs 177 21 29 20 30
Sow/piglet No. of farms with viremic pigs 1/7 3/7 1/6 3/7 0/6
S/P ratio   1.76 ± 0.21 0.93 ± 0.12 0.62 ± 0.08 1.04 ± 0.13 1.89 ± 0.26
No. of tested pigs 43 36 30 36 30
The non-vaccinated No. of farms with viremic pigs 0/7 2/7 5/5 4/5 3/5
S/P ratio   1.12 ± 0.14 0.98 ± 0.11 0.67 ± 0.08 0.83 ± 0.13 0.87 ± 0.11
No. of tested pigs 48 37 29 29 29
*MLV vaccinating schedules: Sow (MLV vaccination on the sow group only, usually at nursery or mass vaccination with 3 months of interval),
Sow/piglet (MLV vaccination on sows and piglets at 2∼4 weeks of age). 
†S/P  ratio (mean ± SE): S/P ratio obtained from commercial ELISA kit,
S/P ratio of ≥ 0.4 regarded as sero-positive to PRRSV.  
‡No. of farms with viremic pigs / No. of tested farms.
farms at 9 and 12 weeks of age.  However, mean S/P ratios 
were above 0.4 in all age groups, which meant that they 
were seroconverted for PRRSV.
Phylogenetic relationship of total Korean PRRSV 
ORF5 sequences with those of other countries
  The neighbor-joining tree was presented in Fig. 1. Korean 
specific subgroups (Ksg)-1, 2 and subgroup 3 were 
clustered near the VR-2332-like subgroup. The majority of 
the PRRSV samples collected from 2007 to 2008 were 
shown to belong to Ksg-4, which was previously reported 
by Cha et al. [7]. There was no subgroup-specific differences 
between viruses from MLV-vaccinating or non-vaccinating 
farms. The viruses of the Ksg-4 subgroup had 87.8-89.0% 
of nucleotide similarity with VR-2332 in the ORF5 region. 
The recent Korean PRRSVs from 2007 to 2008 made a 
novel subgroup which was not reported by Cha et al. [7] 
and were in the same cluster with MN184 strain from USA. 
The PRRSVs in this subgroup (MN184-like) had a 
similarity of 90.3∼90.5% compared to MN184 and 84.9∼
87.2% compared to the MLV on nucleotides of the ORF5 
region. The type I Korean PRRSVs were clustered with a 
27-2003 strain from Spain with 89.1∼91.7% of similarity. 
The Korean type I PRRSV had 84.9∼88.4% of similarity 
in ORF5 when compared with a European-like PRRSV 
strain (SD-02-11, Genbank Accession no. AY395078) 
isolated from USA.
Evolution of type II Korean PRRSV from 1997 to 
2008
  To observe the evolutionary pattern of type II PRRSV 
from 1997 to 2008, a Maximum parsimony tree was drawn 
(Fig. 2). The type II Korean PRRSVs were shown to have 
been evolved into four subgroups, subgroups 1, 2, 3 and 4. 
Subgroup 1 included a PL97-1, a prototype of type II Korean 
PRRSV. The previously reported Ksg-1 and 2 subgroups 
were shown to belong to subgroup 1 and 24% (6/25) of 
recent type II Korean PRRSVs from 2007 to 2008, were 
also included in this group. Subgroup 2 containing Ksg-3 
had only PRRSVs from samples taken as of 2000 to 2003. 
The subgroup 3 formed a novel cluster which was not 
reported before in Korea and had a MN184-like cluster. 
28% (7/25) of recent PRRSVs belonged to this subgroup. 
Subgroup 4 consisted of 48% (12/25) of recent PRRSVs 
and was consistent with previously reports of the Ksg-4 
subgroup.
Analysis of deduced amino acid sequences of type II 
PRRSV ORF5 in the viremic sera
  The amino acid sequences of 23 type II PRRSV ORF5 in 
the viremic sera taken from 2007 to 2008 were aligned to 
compare several epitope regions (Fig. 3). The Ksg-4- 
containing subgroup had at least one mutated sequences at 
H
38, L
39, L
41 and N
44 (K/Q
38, F/I
39, S
41 and K
44). In the case 
of the 3rd B-cell epitope (182∼200), I
189, R
191 and Q
196 
were frequently replaced by V
189, K
191 and R
196 in those groups. 
The MN184-like subgroup showed the replacement of V
185 
and R
191 to A
185 and K
191. The first T-cell epitope (117∼
131) was also a variable region among Korean type II 
PRRSVs obtained from viremic sera. Most common was 
V
124 and A
128 being dominantly replaced by T/I
124 and 
V/T
128 in the Ksg-4-containing subgroup. Notably, the 
ORF5s in MN
184-like subgroup had common mutations 
(FA
127-128 → LT
127-128) which were also observed in the 
isolate CP07-626-2 belonging to this subgroup. The second 
T-cell epitope (149∼163) was more conserved than the 
first T-cell epitope (127∼131) in the ORF5 sequences 
used in this study. The obvious differences of epitope 126    Hye Kwon Kim et al.
Fig. 2. Maximum parsimony tree of type II Korean PRRSV ORF5
from 1997 to 2008. The Lelystad virus, which was a prototype of
type I PRRSV, was used as an outgroup. In the maximum 
parsimony tree, type II Korean PRRSV were mainly divided into
four subgroups, subgroup 1, 2, 3 and 4. Ksg-1 and 2 were in the 
same group, subgroup 1, in this study. Subgroup 2 only contained
samples from 2000 to 2003. The MN184-like subgroup was 
shown to belong to the subgroup 3 which had not been classified
before in Korea.
Fig. 1. The neighbor-joining (N-J) tree of open reading frame 
(ORF) 5 sequences of porcine reproductive and respiratory 
syndrome virus (PRRSV) in viremic pigs from 2007 to 2008. The
name of viremic sera sequences were presented as ‘I.D-V (or 
not)-Year’, where the ‘V’ means the PRRSV ORF5 sequences 
were from a vaccinating farm. Korean specific subgroup (Ksg)-1,
2, 3 and 4 indicates the phylogenetic groups which were grouped
as Korean PRRSV-specific subgroup when compared with Asian
isolates in the N-J method of a previous paper [7].
regions were not observed between MLV-vaccinating or 
non-vaccinating farms, comparing the viruses in same 
subgroup.
Discussion
  The viremia of heterologous virus after MLV vaccination 
had been reported in several papers.  In previous studies, 
although MLV vaccination could contribute to improve the 
clinical outcome, sporadic viremia was as observed as ever 
after challenge with heterologous viruses [5,34]. Although 
clinical improvement in MLV-vaccinating farms was 
proved in those studies, those results could not reflect the 
actual situation in the field. Since the porcine circovirus 
type 2 (PCV2) became the one of the important pathogens 
causing the postweaning multisystemic wasting syndrome 
(PMWS, now one of the PCV-associated diseases), co- 
infection of other pathogens was the important factor for 
the disease appearance of PMWS.  PRRSV was reported as Genetic analysis of ORF5 of recent Korean PRRSVs    127
Fig. 3. Amino acid sequences of two type II PRRSV isolates and 23 type II PRRSV ORF5 in the viremic sera from 2007 to 2008. The
amino acid sequences were compared with the sequence of MLV. The known B-cell epitopes, epitope A (decoying epitope, 27∼30), 
epitope B (neutralizing epitope, 37∼45) and recently identified region (187∼200) were indicated by small, medium and large boxes, 
respectively. Furthermore, the two T-cell epitope regions of GP5 were also indicated by grey backgrounds.
the crucial factor of PMWS or severe wasting diseases 
when co-infected with PCV2 [1,12,33]. PCV2 was 
frequently detected in the wasting, diarrheic pigs and 
aborted fetuses in Korea [2,16,17]. Most farms in this 
study suffered from wasting during the nursery period 
(around 4-9 weeks of age) and several farms were shown to 
be infected with PCV2. Therefore, the viremia of 
vaccine-like virus or heterologous PRRSV observed even 
after MLV-vaccination might be the risk of wasting 
diseases when PCV2 was endemic in the farms, as viremia 
indicated the active replication of PRRSV [13]. 
  In the pilot study, we could also observe sporadic viremia 
even in the seropositive herds of MLV-vaccinating farms 
applying vaccine schedules, such as sow-only and sow- 
piglet scheme. From this observation, this study focused on 
analyzing the PRRSVs obtained from the sera of viremic 
pigs in MLV-vaccinating or non-vaccinating farms. The 
PRRSV viremic pigs were frequently detected in both 
farms. Although high genetic variation was observed 
among the ORF5 of these viruses, there was no considerable 
differences between viruses from MLV-vaccinating or 
non-vaccinating farms. Since Korean swine farms were 
located not so far from the other farms and pigs were 
transferred on a national basis, frequent viral transmission 
‘from farm to farm’ may be a factor for this observation. To 
understand vaccine pressure on PRRSV evolution, a 
long-term chronological study in the evolution of prevailing 
PRRSV after MLV vaccination should be performed on a 
farm to farm basis to reduce interfering factors such as 
transmission of foreign viruses.
  There were some different phylogenetic patterns in this 
study which included the recent type II PRRSVs from 2007 128    Hye Kwon Kim et al.
to 2008. A new subgroup with 84.9∼87.2% similarity of 
ORF5 compared to the MLV was identified. This subgroup 
consisted of only isolates collected from 2007 to 2008. In 
the neighbor-joining tree, they were shown to be closely 
related with MN184 strain from USA, showing 90.3∼
90.5% of similarity. Since USA is the major trade partner 
for the swine industry, these newly identified MN184-like 
viruses might have been introduced from USA one day and 
evolved in Korea independently. 
  The successful adaptation the CP07-626-2 strain, belonging 
to the MN184-like subgroup, on MARC-145 cells (passage 
10), could be used to develop a new vaccine to control 
these newly emerging strains in Korea.
  A Maximum parsimony tree of type II PRRSVs from 
1997 to 2008 showed that the viruses had evolved after first 
introduction of VR-2332-like PRRSV (PL97-1 strain). At 
least 4 lineages were identified in the tree. Although the 
viruses in subgroup 2 were not detected recently, subgroups 
1, 3 and 4 were still detected in Korea. Furthermore, the 
recent type II PRRSVs in subgroups 3 and 4 had high 
variations in their epitope regions of ORF5, including a 
novel B-cell epitope (3rd epitope) and two T-cell epitopes 
[11,38]. The neutralizing antibody fromation was known 
to be greatly affected by genetic variation and the amino 
acid sequences of ORF4 and ORF5 were more correlated 
with the neutralizing ability [19]. Therefore, these frequent 
substitutions in the epitope regions of ORF5 including 
neutralizing epitope also could be a cause of subsequent 
viremia, even in the MLV-vaccinating farms.
  This study also confirmed that the type I PRRSV had been 
co-circulating with type II PRRSV in Korea. The type I 
PRRSV was primarily detected by RT-nested PCR-based 
typing which amplified the ORF6 to ORF7 region, and 
further confirmed by full sequencing of ORF5 in this study. 
The Korean type I PRRSV belonged to the one specific 
subgroup having 87.2∼88.9% similarity in ORF5 
compared to the Lelystad strain, the prototype. Notably, the 
ORF5 of type I Korean PRRSVs were similar with 27∼
003 strain of Spain, not the European-like PRRSV reported 
from the USA. This phylogenetic relationship suggested 
that the type I Korean PRRSVs were possibly introduced 
from Spain and had evolved into a single cluster. Notably, 
since the first report of type I PRRSV in Korea in 2006, the 
detection rate of type I PRRSV had been increasing in the 
field samples [18]. Because of the previously reported 
type-specific protection in the pigs [36,37], the use of type 
I PRRSV-based vaccine should be considered in Korea. 
    The viremia of heterologous PRRSV was frequently 
detected even in the MLV-vaccinating farms. These field 
viruses found in MLV-vaccinating farms were shown to 
have variable nucleotide substitutions on ORF5, similar to 
the non-vaccinating farms. Several substitutions of amino 
acids in the neutralizing epitope were also found in these 
viruses. The genetic diversity in type II PRRSV had been 
increasing from 1997 to 2008 in maximum parsimony tree. 
Furthermore, a newly emerging MN184-like subgroup 
appearing from 2007 was identified, and a circulation of 
type I Korean PRRSV was confirmed in this study. These 
complex situations observed from PRRSV molecular 
epidemiology in Korea reinforce the need for an additional 
vaccine strategy including a new vaccine development. 
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